Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 13Completed 10Active not recruiting 6Not yet recruiting 5Terminated 1Available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

P1b: Advanced Solid Tumors 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × asciminib × Clear all
NCT04492033 2025-01-27

A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients

Handok Inc.

Phase 1/2 Terminated
41 enrolled
GastrointestinalOther solid neoplasm

P1b: Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡